Bebarta Vikhyat S, Garrett Normalynn, Boudreau Susan, Castaneda Maria
Professor, Medical Toxicology, Department of Emergency Medicine, Department of Pharmacology, University of Colorado, School of Medicine, Aurora, Colorado.
CREST Research Program, Department of Emergency Medicine, San Antonio Military Medical Center, Fort Sam Houston, Texas.
Am J Disaster Med. 2015 Autumn;10(3):205-15. doi: 10.5055/ajdm.2015.0203.
To determine if intraosseous (IO) hydroxocobalamin can improve systolic blood pressure (SBP) in a swine model after severe hemorrhagic shock.
Thirty six swine (45-55 kg) were anesthetized, intubated, and instrumented with continuous femoral and pulmonary artery pressure monitoring and then hemorrhaged such that 30 percent of their blood volume was extracted over 20 minutes. Five minutes later, animals were randomly assigned to receive 500 mL IO whole blood, 150 mg/kg IO or intravenous (IV) hydroxocobalamin in 180 mL of saline, or no treatment and then monitored for 60 minutes. A sample size of eight animals per group was based on a power of 80 percent, an alpha of 0.05, and a small effect size to detect a difference in SBP between groups. Outcome data were analyzed using repeated measures analysis of variance (RMANOVA).
RMANOVA outcome analysis detected a significant difference between groups (p < 0.05). IO whole blood, IO hydroxocobalamin, and IV hydroxocobalamin groups were similar to each other, but significantly different compared to controls regarding SBP, mean arterial pressure (MAP), systemic vascular resistance, and heart rate. Differences in SBP and MAP were sustained throughout the experiment. At 60 minutes, the comparison among the groups, IO whole blood, IO hydroxocobalamin, IV hydroxocobalamin, and control, was the following: SBP 78.2 versus 83.7 versus 75.1 versus 55.3 mm Hg; MAP 62.7 versus 65 versus 60 versus 43 mm Hg. There was a significant interaction by time in lactate values (p < 0.01) such that control animal lactate values increased over time (3.3 mmol/L) compared to IO whole blood, IO or IV hydroxocobalamin treated animals (1.1, 1.6, 1.3 mmol/L).
IO hydroxocobalamin improved SBP, MAP, compared to no treatment and was similar to IO whole blood and IV hydroxocobalamin in this animal model of severe hemorrhage. Moreover, whereas serum lactate was improving in all treated groups, it was deteriorating in the control group.
确定在严重失血性休克后的猪模型中,骨内注射(IO)羟钴胺素是否能改善收缩压(SBP)。
36头猪(45 - 55千克)麻醉、插管,并安装用于持续监测股动脉和肺动脉压的设备,然后在20分钟内抽取其30%的血容量进行出血处理。5分钟后,将动物随机分为四组,分别接受500毫升骨内全血、150毫克/千克骨内或静脉注射(IV)羟钴胺素(溶于180毫升生理盐水中),或不进行治疗,然后监测60分钟。每组8只动物的样本量是基于80%的检验效能、0.05的α值以及检测组间SBP差异的小效应量确定的。使用重复测量方差分析(RMANOVA)对结果数据进行分析。
RMANOVA结果分析检测到组间存在显著差异(p < 0.05)。骨内全血组、骨内羟钴胺素组和静脉注射羟钴胺素组彼此相似,但在SBP、平均动脉压(MAP)、全身血管阻力和心率方面与对照组相比有显著差异。SBP和MAP的差异在整个实验过程中持续存在。在60分钟时,骨内全血组、骨内羟钴胺素组、静脉注射羟钴胺素组和对照组之间的比较结果如下:SBP分别为78.2、83.7、75.1和55.3毫米汞柱;MAP分别为62.7、65、60和43毫米汞柱。乳酸值在时间上存在显著交互作用(p < 0.01),与骨内全血组、骨内或静脉注射羟钴胺素治疗的动物相比,对照组动物的乳酸值随时间升高(3.3毫摩尔/升),而上述治疗组的乳酸值分别为1.1、1.6、1.3毫摩尔/升。
在这个严重出血的动物模型中,与不治疗相比,骨内注射羟钴胺素可改善SBP和MAP,且与骨内全血和静脉注射羟钴胺素相似。此外,所有治疗组的血清乳酸值都在改善,而对照组的血清乳酸值却在恶化。